¿Cómo paga?

Cómo pagar lo menos posible

Lo administra su equipo médico

Lo factura la clínica

Virazole lo administra un médico o una enfermera; no se recoge en una farmacia.

Qué hacer

  1. Antes de su cita, pregunte a su equipo médico o a su plan cuánto pagaría.

Su equipo médico y su seguro deciden qué producto recibe.

Compare todas las opciones

De marca

Virazole ya no se vende con receta.

No se vendeYa no se vende

Genérico autorizado

El mismo medicamento que Virazole, sin el nombre de marca

Sin seguroPregunte en la farmacia
Cómo pedirlo

El NDC que debe pedir

El mismo medicamento que Virazole, sin el nombre de marca. Su NDC es el número que identifica el producto exacto: déselo a la farmacia para que lo busquen o lo pidan.

Se vende como

ribavirin

Lo vende
  • Oceanside PharmaceuticalsParte de Bausch Health, la compañía de Virazole

Lo administra su equipo médico

Se administra como tratamiento inhalado en el hospital; no se recoge en una farmacia.

  1. NDC (para su equipo médico)

    • 6 gpolvo para solución
      • 68682-019-01El mismo número, con 11 dígitos: 68682-0019-011 vial
      • 68682-019-06El mismo número, con 11 dígitos: 68682-0019-064 viales por caja
  2. Qué preguntarle a su equipo médico

    “¿Qué versión de Virazole usan: el medicamento de marca o el genérico autorizado? ¿Cuánto pagaría por cada uno?”

Fuente: FDA, actualizado el 16 de noviembre de 2026

Etiquetas de la marca y del genérico autorizado

Etiquetas oficiales y listas de ingredientes de DailyMed (Biblioteca Nacional de Medicina de EE. UU.). Los ingredientes aparecen en inglés, como en la etiqueta.

Virazole ya no se vende, así que no hay una etiqueta de marca actual para comparar. Esta es la etiqueta del genérico autorizado.

Genérico autorizadoOceanside Pharmaceuticals
Ver los ingredientes

Activo: ribavirin 6 g

Genérico regular

No se vende ninguno. El genérico autorizado es el único genérico.

No se vendeNo se vende

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.

Only severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.

Use of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see WARNINGS and DOSAGE AND ADMINISTRATION).

Diagnosis

RSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence3,4 or ELISA5 before or during the first 24 hours of treatment. Treatment may be initiated while awaiting rapid diagnostic test results. However, treatment should not be continued without documentation of RSV infection. Non-culture antigen detection techniques may have false positive or false negative results. Assessment of the clinical situation, the time of year and other parameters may warrant reevaluation of the laboratory diagnosis.

Description of Studies

Non-Mechanically Ventilated Infants: In two placebo-controlled trials in infants hospitalized with RSV lower respiratory tract infection, aerosolized Ribavirin for Inhalation Solution, USP treatment had a therapeutic effect, as judged by the reduction in severity of clinical manifestations of disease by treatment day 3.3,4 Treatment was most effective when instituted within the first 3 days of clinical illness. Virus titers in respiratory secretions were also significantly reduced with Ribavirin for Inhalation Solution, USP in one of these original studies.4 Additional controlled studies conducted since these initial trials of aerosolized Ribavirin for Inhalation Solution, USP in the treatment of RSV infection have supported these data.

Mechanically Ventilated Infants: A randomized, double-blind, placebo-controlled evaluation of aerosolized Ribavirin for Inhalation Solution, USP at the recommended dose was conducted in 28 infants requiring mechanical ventilation for respiratory failure caused by documented RSV infection.6 Mean age was 1.4 months (SD, 1.7 months). Seven patients had underlying diseases predisposing them to severe infection and 21 were previously normal. Aerosolized Ribavirin for Inhalation Solution, USP treatment significantly decreased the duration of mechanical ventilation required (4.9 vs. 9.9 days, p=0.01) and duration of required supplemental oxygen (8.7 vs. 13.5 days, p=0.01). Intensive patient management and monitoring techniques were employed in this study. These included endotracheal tube suctioning every 1 to 2 hours; recording of proximal airway pressure, ventilatory rate, and FlO2 every hour; and arterial blood gas monitoring every 2 to 6 hours. To reduce the risk of Ribavirin for Inhalation Solution, USP precipitation and ventilator malfunction, heated wire tubing, two bacterial filters connected in series in the expiratory limb of the ventilator (with filter changes every 4 hours), and water column pressure release valves to monitor internal ventilator pressures were used in connecting ventilator circuits to the SPAG®-2.

Employing these techniques, no technical difficulties with Ribavirin for Inhalation Solution, USP administration were encountered during the study. Adverse events consisted of bacterial pneumonia in one case, staphylococcus bacteremia in one case and two cases of post-extubation stridor. None were felt to be related to Ribavirin for Inhalation Solution, USP administration.

Fuente: la etiqueta de la FDA de Ribavirin (Oceanside Pharmaceuticals), 1 de mayo de 2019. Etiqueta completa en DailyMed 

Datos útiles

  • Puede verse diferente de Virazole (color, forma o lo que tiene grabado o impreso). Eso es normal en un genérico autorizado.
  • Si su receta dice “dispense as written” (surtir tal como está escrito), la farmacia necesita la autorización de su médico para darle el genérico autorizado.
  • La cobertura depende de su plan. Su equipo médico o su aseguradora le pueden decir cuánto pagaría.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.